Staff Profiles
Saimir Luli
Imaging Facility Manager(preclin in viv)
- Email: saimir.luli@ncl.ac.uk
- Telephone: 0191 208 5126
- Personal Website: https://www.ncl.ac.uk/pivi/
- Address: Fibrosis Research Group
Institute of Cellular Medicine
4th Floor, William Leech Building
Newcastle University
Newcastle upon Tyne
NE2 4HH
Publications
- Zeybel M, Luli S, Sabater L, Hardy T, Oakley F, Leslie J, Page A, Salvador EM, Sharkey V, Tsukamoto H, Chu DCK, Singh US, Ponzoni M, Perri P, Di Paolo D, Mendivil EJ, Mann J, Mann DA. A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. Molecular Therapy 2017, 25(1), 218-231.
- Luli S, Di Paolo D, Perri P, Brignole C, Hill SJ, Brown H, Leslie J, Marshall HL, Wright MC, Mann DA, Ponzoni M, Oakley F. A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo. Journal of Hepatology 2016, 65(1), 75-83.
- Wilson CL, Jurk D, Fullard N, Banks P, Page A, Luli S, Elsharkawy AM, Gieling RG, Bagchi-Chakraborty J, Fox C, Richardson C, Callaghan K, Blair GE, Fox N, Lagnado A, Passos JF, Moore AJ, Smith GR, Tiniakos DG, Mann J, Oakley F, Mann DA. NFkB1 is a suppressor of neutrophil-driven hepatocellular carcinoma. Nature Communications 2015, 6, 6818.
- Moles A, Sanchez AM, Banks PS, Murphy LB, Luli S, Borthwick L, Fisher A, O'Reilly S, van Laar JM, White SA, Perkins ND, Burt AD, Mann DA, Oakley F. Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response. Hepatology 2013, 57(2), 817-828.